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Abstract 
We report the case of a 52-year-old woman with advanced colorectal cancer who was 
treated with oxaliplatin on a FOLFOX schedule. After 3 cycles of chemotherapy, she 
started to complain of visual loss, altered color vision and neurological symptoms. Due 
to the suspicion of ocular and neurological toxicity, antineoplastic treatment was 
stopped. Her visual field showed a concentric bilateral scotoma and the 
electrooculogram test revealed severe impairment of the retinal pigment epithelium. 
Visual acuity, color vision and visual field recovered completely 8 months later, although 
electrooculogram remained abnormal. Ocular toxicity has been reported as an 
infrequent adverse event of oxaliplatin. Findings in this case indicate toxicity of this 
chemotherapeutic agent on the retinal pigment epithelium, which has not been 
reported before. This damage could be permanent, and it thus differs from previously 
described oxaliplatin-induced ocular toxicities, which are usually transient and 
reversible. With increasing use of oxaliplatin as first-line treatment in advanced 
colorectal cancer, we have to be aware of this possible toxicity. 
 
Introduction 
Oxaliplatin is a third-generation platinum-based chemotherapy used in the first-line 
treatment of advanced colorectal cancer [1]. Main side effects associated to this drug are 
neurotoxicity, mild hematological toxicity (neutropenia, thrombocytopenia, and anemia) 
and gastrointestinal symptoms (nausea, vomiting and/or diarrhea). Oxaliplatin-induced 
neurotoxicity is a prominent side effect and has emerged as the major dose-limiting  
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toxicity [2, 3]. Two different types of neurotoxicity have been described [3–5]. The first 
type, acute neurotoxicity, develops immediately following infusion and is characterized by 
transient paresthesia and muscular spasm, often induced or aggravated by exposure to 
cold. The second type, chronic neurotoxicity, produces sensory dysfunction with distal 
dysesthesias and paresthesias that can lead to sensory ataxia and functional impairment of 
fine sensorimotor coordination. It is a dose-dependent and cumulative toxicity. 
Symptoms are generally reversible, although they sometimes may persist in the long term 
in spite of treatment discontinuation [3–5]. 
Ocular toxicity is an uncommon but possible side effect of oxaliplatin. Oxaliplatin has 
been documented to produce a variety of ocular changes, most of them being transient 
and reversible [6]. Reported adverse effects vary from seemingly mild changes, such as dry 
eyes, tearing, conjunctivitis and abnormal lacrimation, to more severe and sometimes 
permanent changes, such as retinal damage or visual field cuts [6]. Patients receiving 
oxaliplatin therapy may complain of blurred vision, visual loss, tunnel vision, altered 
color vision and other symptoms [7]. The mechanism of this toxicity remains unknown. 
Case Report 
A 52-year-old female patient experienced visual changes while receiving oxaliplatin. After 3 cycles of 
chemotherapy on a FOLFOX-4 schedule (a combination of oxaliplatin, leucovorin and 5-fluorouracil), 
she complained of blurred vision and altered color vision as well as neurological symptoms, such as 
paresthesia of the extremities and laryngeal dysesthesia. Oncologists categorized these symptoms as 
grade-3 neurotoxicity and the patient was referred to our department for evaluation of ophthalmic 
symptoms. 
On examination, the best corrected visual acuity (BCVA) was 15/25 in the right eye (RE) and 20/30 
in the left eye (LE). The Ishihara color test was 11/21 in the RE and 19/21 in the LE. Fundus 
examination did not demonstrate any alteration in the retina or the optic head (fig. 1). Visual field 
examination showed a severe bilateral concentric scotoma with mild central defect (fig. 2), and the 
electrooculogram test revealed a deeply diminished response in both eyes, with an Arden Index <95%. 
Macular and optic nerve optical coherence tomography (OCT) as well as electroretinogram and evoked 
potentials had normal results (fig. 3). Antineoplastic treatment was stopped due to the occurrence of 
neurological and ocular toxicity. Visual disturbances improved progressively 3 weeks after 
chemotherapy discontinuation until complete resolution. Eight months after the onset of ocular 
symptoms, BCVA was 20/20 in both eyes, visual field showed only mild residual defects (fig. 3), and the 
Ishihara color test was 21/21 in both eyes, although electrooculogram remained abnormal. 
Discussion 
Ocular side effects related to chemotherapeutic drugs, although uncommon, have been 
documented with a wide variety of symptoms [8, 9]. In spite of their low frequency, ocular 
toxicities associated to this group of drugs are important because they can potentially lead 
to visual loss and permanent damage of ocular structures [10]. An association between 
chemotherapeutic drugs and visual disturbances is difficult to establish because of their 
low incidence and the coexistence of multiple and simultaneous factors which can lead to 
changes in ocular function and structure [10]. Therefore, patients should be questioned 
about the presence of visual impairments, and healthcare professionals must be alert to 
this possibility to notice any change in visual function. In case of appearance of visual 
changes, a complete ophthalmologic examination must be performed [10], including  
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complementary tests, e.g. computerized perimetry, OCT and electrophysiological tests, 
which can help to unmask ocular toxicity in these patients. 
Oxaliplatin is a platinum-based anticancer drug used in combination with infusional 
5-fluorouracil and leucovorin in the first-line treatment of patients with metastatic 
colorectal cancer [1]. Ocular toxicity related to oxaliplatin is uncommon but possible. It 
has been documented to produce a variety of ocular changes, most of them transient and 
reversible, but sometimes permanent changes occur, such as retinal and optic nerve 
damage. 
Conclusion 
Our findings suggest that oxaliplatin can lead to damage of the retinal pigment 
epithelium and the optic nerve, resulting in visual loss and altered color vision, with 
permanent lesions in the electrooculogram and transient tunnel vision with concentric 
scotoma in the computerized perimetry, resolving after discontinuation of oxaliplatin 
therapy. Although several ocular changes have been reported related to oxaliplatin [6], we 
are unaware of previous reports of toxicity to the retinal pigment epithelium as a 
complication of oxaliplatin treatment. 
In conclusion, healthcare clinicians should be alert to this potential toxicity when 
administering antineoplastic agents, especially platinum compounds like oxaliplatin, in 
order to detect and prevent visual loss and damage to ocular structures. 
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Fig. 1. Retinography. Fundus examination did not show any alteration in the macular area or optic 
disc in both RE (a) and LE (b). 
 
 
 
Fig. 2. Computerized perimetry. a First visual field performed after 1 month without oxaliplatin 
chemotherapy showed a concentric defect with deeply diminished light sensitivity. BCVA was 20/30 in 
the RE and 15/25 in the LE. b After 8 months without oxaliplatin, the visual field shows practically 
complete recovery of light sensitivity in both eyes, with only mild residual defects remaining. BCVA 
was 20/20 in both eyes. 
  
Case Rep Oncol 2010;3:423–427 
DOI: 10.1159/000322675 
Published online: 
November 22, 2010
© 2010 S. Karger AG, Basel 
ISSN 1662–6575 
www.karger.com/cro 
 
 
427
 
Fig. 3. Optical coherence tomography. OCT of the optic nerve head reveals a normal retinal nerve fiber 
layer of both optic discs (RE and LE). 
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